文献速递头颈与中枢神经肿瘤

局部复发鼻咽癌再程IMRT的预后分层模型

Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy.
PubMed 文献 · J Clin Oncol · 2018-02-07

PI在训练集和验证集中对总生存的区分度良好(Harrell's C=0.69-0.72),固定切点252可区分高低危亚组。

要点

  • 5因素PI可区分再程IMRT的高低危患者,高危组总生存显著更差。
  • PI低危患者适合根治性再程IMRT,高危患者需探索新临床试验。
  • PI同时预测总生存和5级毒性无事件率,辅助个体化决策。

核心结论

  • 构建并验证了用于局部复发鼻咽癌再程IMRT临床分层的5因素预后指数。
  • 低危患者是根治性再程IMRT的理想候选,高危亚组需新临床试验。

研究设计与样本

  • 多中心回顾性队列研究,训练集为SYSUCC-A(n=251),验证集为NCCS(n=114)和SYSUCC-B(n=193)。
  • 患者均接受再程IMRT,时间跨度为2001至2015年。
  • 主要终点为总生存(OS),次要终点为5级毒性无事件率(G5-TFR)。

主要发现

  • 训练集中与OS不良相关的因素(按权重升序):复发肿瘤体积(HR 1.01/mL增加,P<.001)、年龄(HR 1.02/年增加,P=.008)、再程IMRT EQD2≥68 Gy(HR 1.42,P=.03)、既往放疗诱导≥3级毒性(HR 1.90,P=.001)、rT分期3-4(HR 1.96,P=.005)。
  • PI对OS的区分度在训练集和验证集相当:Harrell's C=0.71(SYSUCC-A)、0.72(NCCS)、0.69(SYSUCC-B)。
  • 固定PI切点252(来自训练集)在验证集中区分高低危亚组:NCCS HR=3.09(95%CI 1.95-4.89),SYSUCC-B HR=3.80(95%CI 2.55-5.66)。
  • PI预测36个月OS和G5-TFR:高危NCCS预测vs观察为22% vs 15%和38% vs 44%;高危SYSUCC-B为26% vs 31%和45% vs 46%。

关键数值与推荐

  • PI包含5个因素:复发肿瘤体积、年龄、再程IMRT EQD2≥68 Gy、既往放疗诱导≥3级毒性、rT分期3-4。
  • 固定PI评分切点252区分低危和高危亚组。

临床怎么用

  • 可用5因素PI对局部复发鼻咽癌患者再程IMRT前进行风险分层。
  • 低危患者优先推荐根治性再程IMRT,高危患者应考虑临床试验或更谨慎的决策。

局限性

  • 回顾性研究设计,样本来自两个学术机构,外推性需进一步验证。
  • PI切点252基于训练集数据,需在前瞻性队列中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To investigate for a prognostic index (PI) to personalize recommendations for salvage intensity-modulated radiotherapy (IMRT) in patients with locally recurrent nasopharyngeal carcinoma (lrNPC). Methods Patients with lrNPC from two academic institutions (Sun Yat-Sen University Cancer Center [SYSUCC-A; n = 251 (training cohort)] and National Cancer Centre Singapore [NCCS; n = 114] and SYSUCC-B [n = 193 (validation cohorts)]) underwent salvage treatment with IMRT from 2001 to 2015. Primary and secondary clinical end points were overall survival (OS) and grade 5 toxicity-free rate (G5-TFR), respectively. Covariate inclusion to the PIs was qualified by a multivariable two-sided P < .05. Discrimination and calibration of the PIs were assessed. Results The primary PI comprised covariates that were adversely associated with OS in the training cohort (gross tumor volumerecurrence hazard ratio [HR], 1.01/mL increase [ P < .001], agerecurrence HR, 1.02/year increase [ P = .008]; repeat IMRT equivalent dose in 2-Gy fractions [EQD2] ≥ 68 Gy HR, 1.42 [ P = .03]; prior radiotherapy-induced grade ≥ 3 toxicities HR, 1.90 [ P = .001]; recurrent tumor [rT]-category 3 to 4 HR, 1.96 [ P = .005]), in ascending order of weight. Discrimination of the PI for OS was comparable between training and both validation cohorts (Harrell's C = 0.71 [SYSUCC-A], 0.72 [NCCS], and 0.69 [SYSUCC-B]); discretization by using a fixed PI score cutoff of 252 determined from the training data set yielded low- and high-risk subgroups with disparate OS in the validation cohorts (NCCS HR, 3.09 [95% CI, 1.95 to 4.89]; SYSUCC-B HR, 3.80 [95% CI, 2.55 to 5.66]). Our five-factor PI predicted OS and G5-TFR (predicted v observed 36-month OS and G5-TFR, 22% v 15% and 38% v 44% for high-risk NCCS and 26% v 31% and 45% v 46% for high-risk SYSUCC-B). Conclusion We present a validated PI for robust clinical stratification of radioresistant NPC. Low-risk patients represent ideal candidates for curative repeat IMRT, whereas novel clinical trials are needed in the unfavorable high-risk subgroup.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li YQ, Tian YM, Tan SH, et al. Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. J Clin Oncol. 2018. PMID: 29412781. doi:10.1200/JCO.2017.75.5165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。